Page last updated: 2024-09-04

ter 286 and Local Neoplasm Recurrence

ter 286 has been researched along with Local Neoplasm Recurrence in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Boulos, L; Brown, GL; Brown, J; Dombroski, JA; Gomez, RF; Henner, WD; Keck, JG; Laxa, B; Lum, RT; Maack, CA; Mascavage, JC; Reiswig, L; Rosen, LS; Schow, SR1

Reviews

1 review(s) available for ter 286 and Local Neoplasm Recurrence

ArticleYear
Current data and ongoing trials in patients with recurrent non-small-cell lung cancer.
    Clinical lung cancer, 2004, Volume: 5, Issue:6

    Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Cytotoxins; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Glutamates; Glutathione; Guanine; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Paclitaxel; Pemetrexed; Prodrugs; Prognosis; Quinazolines; Taxoids

2004

Trials

1 trial(s) available for ter 286 and Local Neoplasm Recurrence

ArticleYear
Phase I study of TLK286 (glutathione S-transferase P1-1 activated glutathione analogue) in advanced refractory solid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Volume: 9, Issue:5

    Topics: Adult; Aged; Cytotoxins; Dose-Response Relationship, Drug; Female; Glutathione; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms

2003